drugset / Trial / NCT04990609
EUS-RFA PANCARDINAL-1 Trial
Phase 2
Recruiting
60 enrolled
The University of Texas Health Science Center, Houston
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
The objectives of this study are to determine the feasibility, tolerability, and treatment effect of endoscopic ultrasound (EUS) radiofrequency ablation (RFA) plus standard-of-care neoadjuvant chemotherapy (NAC) in the treatment of pancreatic ductal adenocarcinoma (PDAC). Endoscopic ultrasound (EUS) radiofrequency ablation (RFA) and neoadjuvant chemotherapy (NAC) will be performed before tumor resection surgery, with the goal of shrinking a tumor or stopping the spread of cancer so that surgery might be less invasive and more effective.
Timeline
- Start
- 2021-08-13
- Primary completion
- 2026-12-01
- Completion
- 2028-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Gemcitabine | Small molecule | — | — |
| Background | Nab-paclitaxel | Small molecule | — | — |